NPI 1285611871: Open Payments
NPI 1285611871. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,632 in 66 payments from 16 companies in 2025. Trend: 2023 $1,300 · 2024 $1,831 · 2025 $1,632
Food & beverage: $1,632
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 7 | $311 |
| ABBVIE INC. | 13 | $285 |
| PFIZER INC. | 14 | $199 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $193 |
| Axsome Therapeutics, Inc. | 3 | $137 |
| GlaxoSmithKline, LLC. | 5 | $89 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $83 |
| Abbott Laboratories | 1 | $80 |
| Otsuka America Pharmaceutical, Inc. | 3 | $56 |
| Lilly USA, LLC | 2 | $48 |
Products named: CAPLYTA, UBRELVY, Ozempic, Auvelity, Wegovy, ELIQUIS, QULIPTA, Kerendia.
